Overview

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:
0

Participant gender:
All

Summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Samsung Medical Center

Collaborator:

H. Lundbeck A/S

Treatments:

Antidepressive Agents
Citalopram
Dexetimide

Criteria

Inclusion Criteria:

1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical
Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a
semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The
affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the
Korean version of the structured clinical interview for the diagnostic and statistical
manual of mental disorders, Fourth edition.

2. interview with one more patient's family member for objective diagnosis and final
diagnosis decision by agreements of two more psychiatric physicians

Exclusion Criteria:

1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4
weeks

2. potential study participants for pregnancy, significant medical conditions, abnormal
laboratory baseline values, unstable psychiatric features(eg.suicidal), history of
alcohol of drug dependence, seizures, head trauma with loss of consciousness,
neurological illness, or concomitant Axis I psychiatric disorder.